AGC Biologics has unveiled the expansion of its pDNA Center of Excellence in Heidelberg, Germany. The global biopharmaceutical contract development and manufacturing organization (CDMO) is further expanding to meet the growing need for process development and manufacturing for plasmid DNA (pDNA).
 
“It is a priority to keep up with the growing demand for plasmid DNA offerings,” said Patricio Massera, chief executive officer, AGC Biologics.
 
The €1 million investment in a laboratory build-out includes a significant increase of lab area, additional staffing and state-of-the-art equipment, to foster high-throughput techniques and quality by design processes. This will further expand AGC Biologics’ service portfolio and build on a track record of more than seven years in commercial plasmid manufacturing.
 
Kasper Moller, chief technology officer, AGC Biologics, said, “This expansion will enable us to be even more efficient, as we meet our customers’ pDNA demand.”